Rapid Decay of Anti-SARS-CoV-2 Antibodies in Persons with Mild Covid-19
- PMID: 32706954
- PMCID: PMC7397184
- DOI: 10.1056/NEJMc2025179
Rapid Decay of Anti-SARS-CoV-2 Antibodies in Persons with Mild Covid-19
Erratum in
-
Rapid Decay of Anti-SARS-CoV-2 Antibodies in Persons with Mild Covid-19.N Engl J Med. 2020 Sep 10;383(11):e74. doi: 10.1056/NEJMx200017. Epub 2020 Jul 23. N Engl J Med. 2020. PMID: 32706959 No abstract available.
Figures
Comment in
-
Loss of Anti-SARS-CoV-2 Antibodies in Mild Covid-19.N Engl J Med. 2020 Oct 22;383(17):1694-1695. doi: 10.1056/NEJMc2027051. Epub 2020 Sep 23. N Engl J Med. 2020. PMID: 32966710 No abstract available.
-
Loss of Anti-SARS-CoV-2 Antibodies in Mild Covid-19.N Engl J Med. 2020 Oct 22;383(17):1695. doi: 10.1056/NEJMc2027051. Epub 2020 Sep 23. N Engl J Med. 2020. PMID: 32966711 No abstract available.
-
Loss of Anti-SARS-CoV-2 Antibodies in Mild Covid-19.N Engl J Med. 2020 Oct 22;383(17):1695-1696. doi: 10.1056/NEJMc2027051. Epub 2020 Sep 23. N Engl J Med. 2020. PMID: 32966712 No abstract available.
Similar articles
-
Duration of serum neutralizing antibodies for SARS-CoV-2: Lessons from SARS-CoV infection.J Microbiol Immunol Infect. 2020 Oct;53(5):821-822. doi: 10.1016/j.jmii.2020.03.015. Epub 2020 Mar 25. J Microbiol Immunol Infect. 2020. PMID: 32249185 Free PMC article. No abstract available.
-
Low prevalence of IgG antibodies to SARS-CoV-2 in cancer patients with COVID-19.Int J Cancer. 2020 Dec 1;147(11):3267-3269. doi: 10.1002/ijc.33148. Epub 2020 Jun 27. Int J Cancer. 2020. PMID: 32525566 Free PMC article. No abstract available.
-
Reliability and usefulness of a rapid IgM-IgG antibody test for the diagnosis of SARS-CoV-2 infection: A preliminary report.J Infect. 2020 Aug;81(2):e53-e54. doi: 10.1016/j.jinf.2020.04.022. Epub 2020 Apr 23. J Infect. 2020. PMID: 32335175 Free PMC article. No abstract available.
-
Detection of serum immunoglobulin M and immunoglobulin G antibodies in 2019 novel coronavirus infected patients from different stages.Chin Med J (Engl). 2020 Jun 20;133(12):1479-1480. doi: 10.1097/CM9.0000000000000820. Chin Med J (Engl). 2020. PMID: 32221133 Free PMC article. No abstract available.
-
Understanding the COVID-19 pandemic from a gender perspective.Taiwan J Obstet Gynecol. 2020 Nov;59(6):801-807. doi: 10.1016/j.tjog.2020.09.004. Epub 2020 Sep 11. Taiwan J Obstet Gynecol. 2020. PMID: 33218392 Free PMC article. Review.
Cited by
-
Humoral waning kinetics against SARS-CoV-2 is dictated by disease severity and vaccine platform.medRxiv [Preprint]. 2024 Oct 18:2024.10.17.24315607. doi: 10.1101/2024.10.17.24315607. medRxiv. 2024. PMID: 39484236 Free PMC article. Preprint.
-
COVID-19 antibody responses in individuals with natural immunity and with vaccination-induced immunity: a systematic review and meta-analysis.Syst Rev. 2024 Jul 19;13(1):189. doi: 10.1186/s13643-024-02597-y. Syst Rev. 2024. PMID: 39030630 Free PMC article.
-
Seroprevalence of SARS-CoV-2 and risk factors for infection among children in Uganda: a serial cross-sectional study.medRxiv [Preprint]. 2024 Jun 21:2024.06.09.24308673. doi: 10.1101/2024.06.09.24308673. medRxiv. 2024. PMID: 38947039 Free PMC article. Preprint.
-
Application of Interferon-γ Release Assay in the Assessment of T-Cell Immunity to SARS-CoV-2 Antigens in the Cohort of Pediatric Patients with Juvenile Idiopathic Arthritis.Children (Basel). 2024 Jun 16;11(6):736. doi: 10.3390/children11060736. Children (Basel). 2024. PMID: 38929315 Free PMC article.
-
T-cell responses in COVID-19 survivors 6-8 months after infection: A longitudinal cohort study in Pune.Immun Inflamm Dis. 2024 Jun;12(6):e1238. doi: 10.1002/iid3.1238. Immun Inflamm Dis. 2024. PMID: 38860770 Free PMC article.
References
-
- Long Q-X, Tang X-J, Shi Q-L, et al. Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections. Nat Med 2020. June 18 (Epub ahead of print). - PubMed
-
- Cao W-C, Liu W, Zhang P-H, Zhang F, Richardus JH. Disappearance of antibodies to SARS-associated coronavirus after recovery. N Engl J Med 2007;357:1162-1163. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- R01 AI140775/AI/NIAID NIH HHS/United States
- AI124979/National Institute of Allergy and Infectious Diseases/International
- UM1 AI068632/AI/NIAID NIH HHS/United States
- UM1AI068616/National Institute of Allergy and Infectious Diseases/International
- AI140775/National Institute of Allergy and Infectious Diseases/International
- U01 AI068616/AI/NIAID NIH HHS/United States
- UM1AI068632/National Institute of Allergy and Infectious Diseases/International
- UM1 AI068616/AI/NIAID NIH HHS/United States
- K08 DA048163/DA/NIDA NIH HHS/United States
- Grant to OOY/AIDS Healthcare Foundation/International
- UM1 AI106716/AI/NIAID NIH HHS/United States
- 2019086/DDCF_/Doris Duke Charitable Foundation/United States
- U01 AI068632/AI/NIAID NIH HHS/United States
- R21 AI131879/AI/NIAID NIH HHS/United States
- AI131879/National Institute of Allergy and Infectious Diseases/International
- K08 AI124979/AI/NIAID NIH HHS/United States
- UM1AI106716/National Institute of Allergy and Infectious Diseases/International
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous